glp 1 and gip dual agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Spatiotemporal GLP-1 and GIP receptor

This article examines the evidence linking GLP-1 medications to muscle pain, explores potential mechanisms, and provides guidance on when to seek medical attention and how to manage symptoms effectively

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

Antagonizing GIPR adds fire to the GLP-1R flame

In addition to the different study populations and study design in these trials, one potential reason for this heterogeneity in cardiovascular benefit is the structural differences among the GLP-1RAs used in these trials

Several of these drugs (exenatide (Byetta and Bydureon), liraglutide (Victoza for diabetes, Saxenda for obesity) albiglutide (Tanzeum), dulaglutide (Trulicity), and lixisenatide (Lyxumia in Europe, Adlyxin in the United States) have been around for at least ten years